Forecasting Stories

<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#FF6600;color: #FFFAFA;font-size:1.1em;;'>AB</div>
  over two weeks ago at Macroaxis 
By Vlad Skutelnik
Anixa Biosciences Price to Sales Ratio is fairly stable at the moment as compared to the past year. Anixa Biosciences reported Price to Sales Ratio of 352.30 in 2019. Sales per Share is likely to rise to 0.012 in 2020, whereas Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (14.4 M) in 2020. Today's short post will break down Anixa Biosciences as your potential position. We will inspect the question of why investors should continue to be confident in Anixa Biosciences outlook.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#FF0F00;color: #FFFFF0;font-size:1.1em;;'>PC</div>
  over two weeks ago at Macroaxis 
By Gabriel Shpitalnik
Patterson Companies Long Term Debt to Equity is quite stable at the moment as compared to the past year. The company's current value of Long Term Debt to Equity is estimated at 0.74. PPandE Turnover is expected to rise to 20.23 this year, although the value of Net Income Per Employee is projected to rise to (26 K). The underlying goal of this short thesis is to outline Patterson as an investment oportunity for October. We will inspect why recent Patterson Companies price moves suggest a bounce in October.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#FF6600;color: #FFFAFA;font-size:0.9em;;'>CUL</div>
  over three weeks ago at Macroaxis 
By Achuva Shats
Culp Free Cash Flow is very stable at the moment as compared to the past year. Culp reported last year Free Cash Flow of 1.06 Million. As of 2nd of September 2020, Invested Capital Average is likely to grow to about 129.3 M, while Working Capital is likely to drop about 88.2 M. The underlying rationale for this short perspective is to recap Culp as an investment oportunity for October. We will focus on why recent Culp price moves suggest a bounce in October.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#FF6600;color: #FFFAFA;font-size:1.1em;;'>FB</div>
  over three weeks ago at Macroaxis 
By Vlad Skutelnik
The primary objective of this story is to break down Five Below potential for October. We are going to discuss if Five Below is reasonably priced going into October.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#000000;color: #f2f2f2;font-size:1.1em;;'>MS</div>
  over three weeks ago at Macroaxis 
By Raphi Shpitalnik
Matrix Service Current Ratio is fairly stable at the moment as compared to the past year. Matrix Service reported Current Ratio of 1.36 in 2019. EBITDA Margin is likely to rise to 0.0379 in 2020, whereas Net Income Per Employee is likely to drop 5,990 in 2020. Today's short post will break down Matrix Service as your potential position. We will inspect the question of why investors should continue to be confident in Matrix Service outlook.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#FF6600;color: #FFFAFA;font-size:1.1em;;'>AB</div>
  over three weeks ago at Macroaxis 
By Vlad Skutelnik
Avid Bioservices Current Ratio is quite stable at the moment as compared to the past year. The company's current value of Current Ratio is estimated at 1.52. Free Cash Flow per Share is expected to rise to 0.0388 this year, although the value of Average Assets will most likely fall to about 95.9 M. The essential goal of this thesis is to break down our current position on Avid Bioservices for institutional investors considering to short it. We will inspect why Avid Bioservices institutional investors may still consider a stake in the business.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#FF6600;color: #FFFAFA;font-size:1.1em;;'>AT</div>
  over three weeks ago at Macroaxis 
By Achuva Shats
Akcea Therapeutics Net Income Per Employee is projected to increase significantly based on the last few years of reporting. The past year's Net Income Per Employee was at 138,680. The current year Earnings Before Interest Taxes and Depreciation Amortization EBITDA is expected to grow to about 54.5 M, whereas Average Assets are forecasted to decline to about 400 M. Today's short post will go over Akcea Therapeutics as your potential position. We will analyze the question of why investors should continue to be confident in Akcea Therapeutics outlook.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#800000;color: #F8F8FF;font-size:0.9em;;'>NTN</div>
  over three weeks ago at Macroaxis 
By Achuva Shats
Nutanix Revenue to Assets are fairly stable at the moment as compared to the past year. Nutanix reported Revenue to Assets of 0.80 in 2019. Asset Turnover is likely to rise to 0.78 in 2020, whereas Net Income Per Employee is likely to drop (113 K) in 2020. This short post will break down Nutanix as a possible investment alternative for your portfolios. We will provide a perspective on Nutanix future direction.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#4E8BFC;color: #ffffff;font-size:0.9em;;'>RGS</div>
  over three weeks ago at Macroaxis 
By Raphi Shpitalnik
Regis Market Capitalization is relatively stable at the moment as compared to the past year. Regis reported last year Market Capitalization of 665.06 Million. As of 08/30/2020, Tangible Asset Value is likely to grow to about 655.8 M, while Revenue Per Employee is likely to drop slightly above 43.2 K. The primary reasoning behind this post is to break down Regis potential for September. We are going to discuss if Regis is reasonably priced going into September.
<div class='circular--portrait-small' style='padding: 0px; text-align: center; font-weight: 700;background:#FF0F00;color: #FFFFF0;font-size:1.1em;;'>ME</div>
  over three weeks ago at Macroaxis 
By Gabriel Shpitalnik
Today's short post will go over MIDWEST ENERGY as your potential position. We will analyze the question of why investors should continue to be confident in MIDWEST ENERGY outlook.